The Biggest Psychedelic News Stories of the Week – August 28th
Colorado Advances Psychedelic Legalization with Public Input, Cybin Inc. Acquires Small Pharma, and New Studies Highlight Efficacy of Psilocybin Therapy for Cancer and Depression.
Psychedelic Spotlight News
Big Pharma Steps Onto the Psychedelics Wagon
The world of medicine is constantly evolving as more and more research is conducted and breakthroughs are made. One area that has been garnering a lot of attention lately is the use of psychedelics in mental health treatment. And it seems that Big Pharma is taking notice.
‘Psilocybin Has Been Extremely Effective’: Firefighter Advocates for Decriminalization
“There are countless first responders, veterans and people across California who could benefit,” says a retired New York City fireman.
Psilocybin v. Escitalopram: Study Compares Effects on Depression
Researchers probe treating one of the greatest psychological issues of our time with two different drugs.
Over One-Third of Under 50s Are Open to Psychedelic Trials for Mental Health Treatment
Aside from psilocybin, those aged between 18-24 were most interested psychedelic trials with ketamine (27%) and MDMA (26%).
NASA-Inspired Psychedelic Odyssey: Artechouse’s ‘Beyond the Light’ Exhibit Is a Spacetime Trip
Artechouse’s 25-minute cosmic exhibit merges stunning psychedelic imagery, immortalized by NASA’s James Webb Space Telescope, with AI-aided visual production, pushing the boundaries of our imagination and “celebrating the spirit of exploration, discovery, and creation in our universe.”
The Biggest Psychedelic News Stories of the Week – August 21st
Red Light Holland’s psilocybin capsules clear stability tests for Australian distribution, as new research explores psychedelics’ impact on neural synchronization and consciousness, while Oregon’s psilocybin therapy shows promising mental health benefits-but don’t expect insurance coverage just yet.
Removing Barriers of Accessibility to Psychedelics with Brett Waters
Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.
New Study Will Investigate Psilocybin Therapy for Gambling Addiction
Researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin-assisted therapy for gambling addiction, aiming to improve their understanding of brain function in gambling disorder.
30 Days, 30 Psychedelic Retreats – Lessons Learned From Our Quest to Study Central American Retreats and Their Potential to Heal Minds
My journey through 30 retreats made it quite clear that every center has a somewhat unique philosophy of care. With much of the science still early and murky, it’s difficult to say that one approach is better or worse than any others.
End of content
End of content